Modulation of the GDF15-GFRAL axis may also be beneficial for the treatment of other anorexia/cachexia syndromes, for example, end-stage renal disease, heart failure, and COPD, which are all associated with anorexia/cachexia syndromes that confer an adverse prognosis. This evidence concerns the gene GDF15 and heart failure.